Safe to Stop Immunotherapy at 2 Years in Stable Lung Cancer
Immune checkpoint inhibitors are a cornerstone of non–small cell lung cancer treatment. But there is a question that’s been vexing oncologists for years: When can treatment be stopped?
A new review of clinical trial data suggests that it is safe to stop immunotherapy after 2 years if the patient is progression-free. There was no difference in overall survival between such patients and those who carried on with immunotherapy for another 2 years, so for 4 years in total.
"For patients who are progression-free on immunotherapy for NSCLC, it is reasonable to stop therapy at 2 years, rather than continuing indefinitely," said investigators, led by medical oncologist Lova Sun, MD, a lung and head and neck cancer specialist at the University of Pennsylvania, Philadelphia.
Wilt u de rest van dit artikel lezen?
Registreer gratis om toegang te krijgen tot de volledige inhoud van MediQuality op al uw schermen